IL6 and rheumatoid arthritis: A recent double-blind placebo-controlled trial comparing atorvastatin to placebo in 116 RA patients found that atorvastatin significantly reduced disease activity, even after adjustment for MTX, and significantly improved CRP levels and erythrocyte sedimentation rate (ESR) as well as IL-6 and soluble intercellular adhesion molecule-1 (ICAM-1) levels [161].